The DCA Protocol: Dr. Evangelos Michelakis and the Promise of Metabolic Cancer Therapy

The DCA Protocol, arising from research led by Dr. Evangelos Michelakis at the University of Alberta in 2007, represents one of the most compelling and controversial stories in modern cancer research. Based on the use of dichloroacetate (DCA), a simple small molecule with a decades-long history of use in treating rare metabolic disorders in children, the protocol emerged from a fundamental reexamination of the Warburg effect and the role of mitochondria in cancer. This essay explores the origins of the protocol, its elegant scientific rationale, the dramatic preclinical results that generated global excitement, the subsequent clinical investigation, and the complex legacy of a therapy that has inspired both hope and caution in equal measure.

---

1. Introduction: The Mitochondrial Paradigm Shift

In January 2007, Dr. Evangelos Michelakis, a professor at the University of Alberta Department of Medicine and Canada Research Chair in Pulmonary Hypertension, published findings in the journal Cancer Cell that would ignite a firestorm of interest in both the scientific community and the public at large. Michelakis and his colleague Dr. Sebastian Bonnet demonstrated that dichloroacetate, an odorless, colorless, inexpensive small molecule, caused regression in several cancers including lung, breast, and brain tumors .

The significance of this discovery lay not merely in the observed effects but in the fundamental rethinking of cancer biology it represented. Since the 1930s, researchers had known that mitochondria the energy producing units within cells function abnormally in cancer. The prevailing wisdom held that this mitochondrial dysfunction was permanent damage, a consequence rather than a cause of the malignant transformation. Michelakis questioned this assumption. He hypothesized that mitochondrial function was not permanently damaged but rather actively suppressed by the cancer cell as a survival strategy. If this suppression could be reversed, perhaps the cancer cell could be pushed toward normal apoptosis .

DCA offered a tool to test this hypothesis. Scientists and doctors had used DCA for decades to treat children with inborn errors of metabolism due to mitochondrial diseases. Its safety profile and pharmacokinetics were well understood. What Michelakis and his team discovered was that DCA could normalize mitochondrial function in cancer cells, and more importantly, that this normalization resulted in significant tumor growth inhibition both in laboratory models and in animals. Equally significant, DCA appeared to spare normal, non-cancerous tissues .

2. The Foundational Philosophy: Targeting the Warburg Effect

The DCA Protocol is built upon a profound insight into cancer metabolism first articulated by Otto Warburg nearly a century ago. In the 1920s, Warburg observed that cancer cells exhibit a distinctive metabolic pattern: even in the presence of adequate oxygen, they preferentially metabolize glucose to lactate through glycolysis rather than fully oxidizing it in mitochondria. This phenomenon, known as aerobic glycolysis or the Warburg effect, has been confirmed as a hallmark of most aggressive cancers .

For decades, researchers interpreted the Warburg effect as evidence that cancer cell mitochondria were irreversibly damaged. The shift to glycolysis was seen as a compensatory mechanism necessitated by dysfunctional organelles. Michelakis challenged this interpretation. He proposed that mitochondrial suppression was not a passive consequence of damage but an active, reversible strategy employed by cancer cells to gain two critical advantages.

First, by suppressing mitochondrial glucose oxidation, cancer cells redirect metabolic intermediates toward biosynthetic pathways required for rapid proliferation. Second, and perhaps more importantly, dysfunctional mitochondria fail to initiate apoptosis, the programmed cell death that normally eliminates damaged or dangerous cells. Cancer cells thus achieve resistance to apoptosis, a fundamental barrier to tumor development .

DCA targets this vulnerability directly. By inhibiting pyruvate dehydrogenase kinase (PDK), DCA reactivates the pyruvate dehydrogenase complex, the enzyme gateway that allows carbohydrate metabolites to enter the mitochondria for complete oxidation. This metabolic shift from glycolysis to oxidative phosphorylation has profound consequences for cancer cell survival .

3. The Central Agent: Understanding Dichloroacetate

Dichloroacetate is a simple halogenated carboxylic acid with the chemical formula C2H2Cl2O2. Its small size approximately 150 daltons makes it highly bioavailable and capable of penetrating tissues that larger molecules cannot reach, including crossing the blood-brain barrier to reach brain tumors .

DCA's primary mechanism of action is inhibition of pyruvate dehydrogenase kinase, an enzyme that phosphorylates and inactivates the pyruvate dehydrogenase complex. By blocking PDK, DCA maintains the pyruvate dehydrogenase complex in its active, dephosphorylated state, allowing pyruvate to enter the mitochondria and feed into the Krebs cycle .

Note: While DCA does inhibit all four PDK isoforms, it shows preferential activity against PDK2 and PDK4 over PDK1 and PDK3.

The downstream effects of this metabolic shift are multiple and synergistic. Increased mitochondrial glucose oxidation generates reactive oxygen species, which in turn activate redox-sensitive potassium channels in the mitochondrial membrane. This leads to mitochondrial depolarization and the release of pro-apoptotic proteins such as cytochrome c into the cytoplasm. Simultaneously, DCA decreases expression of survivin, an anti-apoptotic protein that helps cancer cells evade programmed death .

Importantly, DCA also upregulates the expression of voltage-gated potassium channels on the cancer cell surface. Efflux of potassium ions through these channels further promotes apoptosis. These effects are not observed in normal cells, which already maintain functional mitochondria and appropriate potassium channel expression, explaining the relative selectivity of DCA for malignant tissue .

4. The 2007 Discovery and Preclinical Evidence

Michelakis and his team's 2007 publication in Cancer Cell presented a series of experiments that systematically built the case for DCA as an anticancer agent. In cell culture studies, DCA induced apoptosis in multiple cancer cell lines while sparing normal cells. In animal models, DCA administration significantly reduced tumor growth with minimal toxicity .

The team also provided mechanistic evidence linking these effects to mitochondrial reactivation. They demonstrated that DCA treatment depolarized the hyperpolarized mitochondrial membrane characteristic of cancer cells, increased reactive oxygen species production, and activated the mitochondrial apoptosis pathway. These findings were later confirmed by independent research groups across the world .

One of the most exciting aspects of the discovery was the potential breadth of application. Because all cancers, regardless of tissue of origin, exhibit suppression of mitochondrial function and the Warburg effect, Michelakis hypothesized that DCA might be effective against many different tumor types. This hypothesis was supported by PET scan technology, which detects the unique metabolic profile of cancers based on their glucose avidity, confirming that metabolic reprogramming is a universal feature of malignancy .

5. The Glioblastoma Study: Translating Mechanism to Patients

Building on the preclinical findings, Michelakis and his colleagues, including neurosurgeon Dr. K.C. Petruk, undertook a challenging translational study in patients with glioblastoma, one of the most aggressive and treatment-resistant brain tumors. Over a two-year period, the team extracted glioblastomas from 49 patients and studied them within minutes of surgical removal, demonstrating that tumors responded to DCA by altering their metabolism exactly as predicted by laboratory experiments .

The team then treated five patients with advanced glioblastoma, securing tumor tissue both before and after DCA therapy. Comparison of the paired samples confirmed that DCA worked in human tumors through the same mechanisms identified in preclinical models. This was a crucial validation, as results in laboratory models do not always translate to patients .

In the five treated patients, DCA took approximately three months to reach blood levels sufficient to alter tumor metabolism. At these levels, there were no significant adverse effects, though at higher doses tested, peripheral neuropathy manifesting as numbness in toes and fingers was observed. Importantly, some patients showed evidence of clinical benefit, with tumors either regressing in size or remaining stable during the 18-month study period .

The research team emphasized that no definitive conclusions about safety or efficacy could be drawn from such a small patient cohort. They stressed that use of DCA by patients or physicians outside the setting of supervised clinical trials, particularly when obtained from for-profit sources, would be inappropriate and potentially dangerous. Nevertheless, the results were encouraging and supported the need for larger clinical trials .

6. Clinical Trial Landscape: Promise and Peril

The subsequent clinical investigation of DCA for cancer has produced a complex and sobering picture that illustrates the gap between elegant basic science and the realities of human disease.

Phase I Trials

A Phase I dose escalation study conducted at the Cross Cancer Institute in Edmonton, Canada, beginning in December 2007, established the safety and tolerability of DCA in patients with recurrent or metastatic solid tumors. The trial employed a starting dose of 12.5 mg per kilogram per day in adult cancer patients, based on safety considerations derived from prior use in metabolic disorders . The study aimed to determine the maximum tolerated dose and to document any antitumor activity, though as a Phase I trial, efficacy was not the primary endpoint.

The UCLA Phase II Trial

A Phase II open-label, single-arm trial was initiated at the University of California, Los Angeles in December 2009, sponsored by the Jonsson Comprehensive Cancer Center. The study was designed to determine the response rate by RECIST criteria of oral DCA in patients with previously treated metastatic breast cancer or advanced non-small cell lung cancer .

Patients received DCA at 6.25 milligrams per kilogram orally twice daily. The trial enrolled only seven patients before being closed prematurely. According to the study record on ClinicalTrials.gov, closure was based on safety concerns, with a Data Safety Monitoring Board determining that there was "higher than expected risk/safety concerns" .

Detailed results subsequently published revealed the reasons for concern. Within the small cohort, one patient died suddenly of unknown cause within one week of initiating DCA, and another patient experienced a fatal pulmonary embolism. Two patients withdrew consent within a week of enrollment. Two patients had disease progression before their first scheduled scans. The single breast cancer patient enrolled had stable disease after eight weeks but quickly progressed in the brain. The investigators concluded that patients with previously treated advanced NSCLC did not benefit from oral DCA, though they noted that in the absence of a larger controlled trial, firm conclusions regarding the association between the adverse events and DCA could not be drawn .

The University of Florida Brain Tumor Trial

A Phase I trial of DCA in recurrent malignant brain tumors was conducted at the University of Florida, beginning in April 2010. This study enrolled 15 patients with either World Health Organization grade III-IV glioma that had recurred at least once or brain metastases from solid tumors. Patients received DCA at doses of 4 milligrams per kilogram or 12.5 milligrams per kilogram twice daily in 30-day cycles .

The primary outcome was determination of safety and tolerability, with secondary exploratory investigation of tumor metabolites and DCA effects. The study was completed in March 2014, and while full results have not been published in peer-reviewed form, the trial demonstrated that DCA could be administered to brain tumor patients with careful monitoring .

7. Comprehensive Mechanisms of Action

The therapeutic potential of DCA rests on a sophisticated understanding of cancer metabolism that has been refined through decades of research. Multiple interconnected pathways contribute to its effects.

Pyruvate Dehydrogenase Kinase Inhibition

DCA is a pan-inhibitor of pyruvate dehydrogenase kinase, the enzyme that phosphorylates and inactivates the pyruvate dehydrogenase complex. By blocking PDHK, DCA maintains PDH in its active form, allowing pyruvate to enter the mitochondria and be converted to acetyl-CoA for entry into the Krebs cycle. This shifts cellular metabolism from glycolysis toward oxidative phosphorylation .

Mitochondrial Membrane Depolarization

Cancer cells typically maintain a hyperpolarized mitochondrial membrane, which contributes to their resistance to apoptosis. DCA-induced metabolic reactivation leads to increased production of reactive oxygen species, which activate redox-sensitive potassium channels in the mitochondrial membrane. Efflux of potassium ions through these channels depolarizes the membrane, triggering opening of the mitochondrial permeability transition pore and release of pro-apoptotic proteins .

Apoptosis Induction Through Multiple Pathways

The released cytochrome c activates the caspase cascade, executing programmed cell death. DCA also decreases expression of survivin, an inhibitor of apoptosis that is often overexpressed in cancer. Simultaneously, DCA upregulates voltage-gated potassium channels on the cell surface, and the resulting potassium efflux further promotes apoptosis .

Reversal of the Warburg Effect

By restoring mitochondrial function, DCA reverses the metabolic phenotype that characterizes aggressive cancers. This not only sensitizes cells to apoptosis but also deprives them of the biosynthetic intermediates generated by aerobic glycolysis that support rapid proliferation .

Cancer Stem Cell Targeting

The glioblastoma study provided evidence that DCA affects cancer stem cells, the subpopulation of tumor cells thought responsible for recurrence and treatment resistance. By altering metabolism in these cells, DCA may address a fundamental driver of therapeutic failure .

8. Safety Profile, Toxicity, and Clinical Considerations

DCA has a well-characterized safety profile from decades of use in metabolic disorders, but this experience must be interpreted carefully when considering oncologic applications.

Peripheral Neuropathy

The most significant and dose-limiting toxicity of DCA is peripheral neuropathy. In adult patients with MELAS syndrome treated with DCA at 25 to 50 milligrams per kilogram daily for six months, a high incidence of neuropathy was observed. However, interpretation is complicated by the fact that neuropathy is part of the MELAS syndrome itself, and many affected patients develop diabetes mellitus, which commonly causes neuropathy. In contrast, children with congenital acidosis treated with similar doses for up to two years did not develop neuropathy .

Clinical trials in cancer patients have employed careful screening to exclude individuals with preexisting neuropathy and have monitored patients closely using quantitative sensory testing. The glioblastoma study reported that at doses sufficient to alter tumor metabolism, no significant adverse effects occurred, though higher doses caused numbness in toes and fingers . The UCLA trial's serious adverse events, including one sudden death and one fatal pulmonary embolism, raised concerns that cannot be fully resolved given the small sample size .

Gastrointestinal Effects

Nausea and other gastrointestinal symptoms have been reported with DCA administration, though these are generally manageable and reversible.

Hepatotoxicity

Transient elevations in liver enzymes have been observed, necessitating monitoring of hepatic function during treatment. These elevations are typically reversible upon dose adjustment or discontinuation .

Drug Interactions

Important drug interactions must be considered. DCA may interact with anticoagulants, and the UCLA trial specifically excluded patients receiving Coumadin while allowing heparin or low molecular weight heparin . Patients on multiple medications require careful evaluation for potential interactions.

Contraindications

Clinical trials have established important exclusion criteria that inform safe use. These include preexisting peripheral neuropathy of any grade, active central nervous system metastases, significant renal or hepatic impairment, and conditions that might impair DCA absorption such as inflammatory bowel disease or malabsorption syndromes. The potential for increased urinary oxalate excretion also raises concerns about nephrolithiasis in susceptible individuals .

9. Current Evidence and Research Gaps

As of 2024 and 2025, multiple comprehensive reviews have assessed the evidence for DCA in cancer treatment, revealing a complex picture that remains far from settled.

Scoping Review Findings

A scoping review published in 2024 identified 12 articles reporting on DCA use in adult cancer patients, with most being individual case reports. The review found a high degree of heterogeneity among studies, making pooled analysis difficult. The most frequent adverse events were asthenia, reversible toxicity, and increased liver enzymes. Importantly, the reviewers concluded that therapeutic effectiveness was difficult to evaluate and that there is currently insufficient evidence to affirm that treatment with DCA in cancer patients is either effective or safe .

The Controversy and Uncertainty

A 2024 review in Pharmaceuticals characterized DCA as a chemical that has elicited unusual controversy. Initially considered a dangerous toxic industrial waste, then a potential treatment for lactic acidosis, DCA's status became contentious following the 2007 publications suggesting anticancer effects. Despite 50 years of experimentation, the compound's future in therapeutics remains uncertain .

The review noted that without adequate clinical trials and health authority approval, DCA has been introduced in off-label cancer treatments in alternative medicine clinics in Canada, Germany, and other European countries. This off-label use, often by individuals without medical training, has further complicated scientific assessment and discouraged consideration by the mainstream research community .

Combination Therapy Potential

Despite the disappointing results of single-agent trials, recent research has suggested that DCA may have greater promise in combination with other agents. A 2025 review highlighted that DCA exerts promising anticarcinogenic properties and shows synergistic effects when combined with other therapeutic agents in multiple cancer models. The combination of DCA with platinum-based chemotherapy, particularly in hypoxic tumors, has been proposed as a more promising approach than single-agent therapy . Another 2025 review in Medicine summarized advances in therapeutic applications of DCA as a metabolic regulator across cancer, metabolic diseases, and inflammatory conditions .

The Challenge of Clinical Translation

The trajectory of DCA research illustrates fundamental challenges in translating compelling mechanistic discoveries into effective therapies. The preclinical data were elegant and reproducible. The mechanism is biologically plausible and targets a universal feature of cancer. Yet when moved into patients with advanced, heavily pretreated disease, the results have been disappointing at best and concerning at worst.

Several factors may explain this gap. Advanced cancer patients enrolled in Phase II trials have typically exhausted standard options and carry heavy disease burdens that may be less responsive to metabolic modulation than early-stage tumors. The dosing regimens derived from metabolic disease experience may not be optimal for oncology applications. The heterogeneity of human tumors means that some cancers may be more dependent on the Warburg effect than others, and patient selection without biomarkers may dilute any true signal.

10. The Patient and Public Phenomenon

Beyond the scientific and clinical dimensions, the DCA story encompasses a remarkable public phenomenon. Following the 2007 publication, patients and families desperate for treatment options began seeking DCA independently, obtaining the compound from compounding pharmacies or online sources. This grassroots movement was fueled by the drug's low cost, its off-patent status, and the compelling narrative of a simple molecule targeting a fundamental cancer vulnerability.

The University of Alberta team repeatedly and explicitly warned against this practice. They emphasized that use of DCA by patients or physicians supplied from for-profit sources or without close clinical observation by experienced medical teams in the setting of research trials was not only inappropriate but potentially dangerous . These warnings were prescient, as the subsequent clinical trial experience demonstrated that DCA is not a benign compound and that its risk-benefit profile remains poorly defined.

The phenomenon also highlighted the challenges of drug development for off-patent compounds. As Michelakis noted in 2007, because DCA is not patented and not owned by any pharmaceutical company, it is difficult to find funding from private investors to conduct clinical trials. He expressed gratitude for support from publicly funded agencies such as the Canadian Institutes for Health Research and hope that such support would continue . In the years since, this funding challenge has proven a significant barrier to the large, well-controlled trials needed to definitively establish DCA's role.

11. Conclusion

The DCA Protocol arising from Dr. Evangelos Michelakis's 2007 discoveries represents a fascinating chapter in the history of cancer research. It embodies the best of hypothesis-driven science: a fundamental reexamination of entrenched dogma, elegant mechanistic experiments, and a clear translational path from laboratory to clinic. The discovery that mitochondrial suppression in cancer is reversible and that reactivation can trigger apoptosis opened new avenues for therapeutic development and reinvigorated interest in cancer metabolism as a target.

Yet the clinical story of DCA has been sobering. The early promise of preclinical models has not translated into clear benefit for patients with advanced cancer in the limited trials conducted to date. The UCLA Phase II trial's early closure due to safety concerns, including fatal adverse events, underscores that DCA is not a harmless metabolic corrector but a pharmacologically active agent with real risks. The heterogeneity of case reports and the absence of controlled data leave fundamental questions unanswered.

Several conclusions can be drawn from the evidence accumulated over nearly two decades. First, the mechanistic rationale for DCA in cancer remains sound and continues to be supported by ongoing research into its multiple pathways of action. Second, single-agent DCA in heavily pretreated advanced cancer patients has not demonstrated compelling efficacy and may carry significant risks. Third, the combination of DCA with other agents particularly platinum-based chemotherapy in appropriately selected patients represents a more promising direction for future investigation. Fourth, the off-label use of DCA outside clinical trials cannot be supported given the current state of evidence.

The story of DCA also offers broader lessons for cancer research and drug development. It illustrates the importance of public funding for investigations that lack commercial sponsorship. It demonstrates the power of patient and public engagement with scientific discovery, for better and for worse. And it highlights the irreducible gap between elegant mechanism and clinical reality a gap that can only be bridged by rigorous, well-designed clinical trials.

The University of Alberta team's original caution remains relevant today: no conclusions about safety or efficacy can be drawn from limited data, and use of DCA outside research settings is inappropriate. Whether DCA will eventually find a place in the oncologic armamentarium, perhaps as part of combination regimens or in biomarker-selected populations, awaits further investigation. For now, it stands as a reminder that in cancer therapeutics, hope must be tempered by evidence, and mechanism must be validated by outcome.

12. Key Published Works and Resources

Original Discovery:

Michelakis ED, et al. Dichloroacetate (DCA) induces apoptosis in cancer cells by inhibiting pyruvate dehydrogenase kinase and promoting mitochondrial oxidative phosphorylation. Cancer Cell. 2007.

Clinical Trials:

Phase I Trial of DCA in Recurrent/Metastatic Solid Tumours, Cross Cancer Institute, Edmonton, Canada. NCT00566410.

Phase II Trial of DCA in Metastatic Breast and Non-Small Cell Lung Cancer, University of California Los Angeles. NCT01029925.

Phase I Trial of DCA in Recurrent Malignant Brain Tumors, University of Florida. NCT01111097.

Recent Reviews:

Koltai T, et al. Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts. Pharmaceuticals (Basel). 2024 Jun 6;17(6):744.

Hunt S, et al. Dichloroacetate and Salinomycin as Therapeutic Agents in Cancer. Med Sci (Basel). 2025 Apr 23;13(2):47.

Bianchi C, et al. Use of sodium dichloroacetate for cancer treatment: a scoping review. Medicina (B Aires). 2024;84(2):313-323.

Wu X, et al. Advances in the therapeutic applications of dichloroacetate as a metabolic regulator: A review. Medicine (Baltimore). 2025 Sep 5;104(36):e44295.